Factory Our Approach
Maze Therapeutics the power of genetics our strategy – applying variant functionalization to precision medicine Using the tools of modern human genetics, the scientific community is learning how
Factory Maze Therapeutics Reports Positive First-in-Human Data from Phase
SOUTH SAN FRANCISCO, CA., October 25, 2024 – Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small
Factory Maze Therapeutics Announces $150 Million Registered Offering
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and
Factory About Us
Maze Therapeutics working to translate genetic insights into effective precision medicines. In the summer of 2018, we had an idea. A big idea, inspired by the recent dramatic advances in the field of
Factory Our Pipeline
Maze Therapeutics advancing R&D in common disease Utilizing Maze Compass™, we are harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living
Factory Maze Therapeutics to Present Additional Data Highlighting the
During the meetings, Maze Therapeutics will present additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, as well as preclinical research supporting inhibition of SLC6A19